Lingohr Asset Management GmbH Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lingohr Asset Management GmbH acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,878 shares of the specialty pharmaceutical company's stock, valued at approximately $354,000.

Other hedge funds also recently bought and sold shares of the company. CIBC Asset Management Inc grew its stake in shares of Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after purchasing an additional 97 shares during the period. UMB Bank n.a. boosted its holdings in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after buying an additional 129 shares during the last quarter. Jones Financial Companies Lllp grew its position in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 130 shares during the period. Waterfront Wealth Inc. grew its position in Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock valued at $1,191,000 after buying an additional 137 shares during the period. Finally, Ellsworth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after buying an additional 149 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on JAZZ shares. HC Wainwright boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Barclays reissued an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $3.26 during midday trading on Monday, reaching $142.02. 969,027 shares of the company were exchanged, compared to its average volume of 705,011. The stock has a market cap of $8.63 billion, a PE ratio of 20.00, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The business's fifty day moving average is $131.41 and its two-hundred day moving average is $121.79. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,022,825 in the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.